Catalina Health adds Safeway to its retail pharmacy network
ST. PETERSBURG, Fla. — Catalina Health on Thursday announced it will complete installation of all Safeway pharmacies into its retail pharmacy network at the end of November. Safeway will be utilizing Catalina Health pharmacy programs to disseminate information to their customers to encourage prescription medication adherence and compliance and advocate healthy lifestyles.
“The Catalina Health program is a wonderful complement to our existing pharmacy services,” said Darren Singer, SVP Safeway. “Educating our patients on the importance of taking their medication and making them aware of our preventive patient care and health services fits right in with Safeway’s strategy of becoming a health-and-wellness destination.”
“The Safeway philosophy aligns completely with our strategic vision and objectives of providing health consumers with the coordinated support they want and need to manage their health and wellness," stated Mark Doerr, Catalina SVP retail services.
Catalina Health develops and delivers relevant treatment-related messages to more than 130 million patients each year with precise, transaction-level insights.
FDA designates Merck hepatitis C drug as breakthrough therapy
WHITEHOUSE STATION, N.J. — The Food and Drug Administration has granted breakthrough therapy designation to an experimental drug made by Merck for hepatitis C, the drug maker said.
The agency gave the designation to MK-5172/MK-8742, a combination pill currently in mid-stage clinical development being investigated as a treatment for hepatitis C genotype 1. The FDA gives breakthrough therapy designation to expedite development and review of drugs planned for use in serious or life-threatening conditions when clinical trial evidence indicates it may represent a substantial improvement over existing therapies.
"There remains significant unmet medical need in hepatitis C, and we are looking forward to working with the FDA to advance this program as quickly as we can to bring this investigational combination to HCV specialists and their patients," Merck Research Labs president Roger Perlmutter said.
BioRx launches hemophilia smartphone app
CINCINNATI — A mobile app described as the specialty pharmacy industry’s first for patients with hemophilia has become available.
Specialty pharmacy and infusion services provider BioRx announced the launch of the app, MyFactor, which it developed to give patients with hemophilia and related bleeding disorders and their caregivers a place to easily monitor and manage their home treatment. The app will be released in the Apple Store next month and allows patients to electronically record bleeding episodes and treatments and share information with their healthcare team, including pharmacists, physicians, nurses and care coordinators.
"MyFactor is the first hemophilia app from a specialty pharmacy," BioRx co-founder Eric Hill said. "This creates a unique platform for BioRx customers and staff to more efficiently communicate and exchange detailed treatment information and helps both parties to anticipate and plan for future needs."
Patients and caregivers can use a "wizard" graphical interface to log details of treatments and bleeding episodes, including type, cause, location and levels of pain and severity, as well as scan barcodes of clotting factor brands and generate customized historical reports in formats like PDF and CSV.